The research team
evaluated the combination of the biologic therapy brentuximab vedotin (Adcetris), a monoclonal antibody - drug conjugate, with the chemotherapy drug
gemcitabine (Gemzar) in 42 pediatric and young - adult patients with Hodgkin lymphoma, the most common cancer in young people ages 15 to 29.